Ruthenium complexes as anticancer agents: A brief history and perspectives

SY Lee, CY Kim, TG Nam - Drug design, development and therapy, 2020 - Taylor & Francis
Platinum (Pt)-based anticancer drugs such as cisplatin have been used to treat various
cancers. However, they have some limitations including poor selectivity and toxicity towards …

The development of anticancer ruthenium (II) complexes: from single molecule compounds to nanomaterials

L Zeng, P Gupta, Y Chen, E Wang, L Ji… - Chemical Society …, 2017 - pubs.rsc.org
Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer
drugs are organic molecules, while metallodrugs are very scarce. The advent of the first …

Hypoxia-targeted drug delivery

A Sharma, JF Arambula, S Koo, R Kumar… - Chemical Society …, 2019 - pubs.rsc.org
Hypoxia is a state of low oxygen tension found in numerous solid tumours. It is typically
associated with abnormal vasculature, which results in a reduced supply of oxygen and …

NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: A case story in medicinal inorganic chemistry

E Alessio, L Messori - Molecules, 2019 - mdpi.com
NAMI-A ((ImH)[trans-RuCl4 (dmso-S)(Im)], Im= imidazole) and KP1019/1339
(KP1019=(IndH)[trans-RuCl4 (Ind) 2], Ind= indazole; KP1339= Na [trans-RuCl4 (Ind) 2]) are …

Metal complexes in cancer therapy–an update from drug design perspective

U Ndagi, N Mhlongo, ME Soliman - Drug design, development and …, 2017 - Taylor & Francis
In the past, metal-based compounds were widely used in the treatment of disease
conditions, but the lack of clear distinction between the therapeutic and toxic doses was a …

Ru (II) compounds: next-generation anticancer metallotherapeutics?

S Thota, DA Rodrigues, DC Crans… - Journal of medicinal …, 2018 - ACS Publications
Metal based therapeutics are a precious class of drugs in oncology research that include
examples of theranostic drugs, which are active in both diagnostic, specifically imaging, and …

Combination of light and Ru (II) polypyridyl complexes: Recent advances in the development of new anticancer drugs

L Conti, E Macedi, C Giorgi, B Valtancoli… - Coordination Chemistry …, 2022 - Elsevier
The increasing impact of cancer on worldwide mortality makes the research of novel
chemotherapeutic agents a current and challenging issue. In the recent years, transition …

Metal drugs and the anticancer immune response

B Englinger, C Pirker, P Heffeter, A Terenzi… - Chemical …, 2018 - ACS Publications
The immune system deploys a multitude of innate and adaptive mechanisms not only to
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …

Thirty years of the drug candidate NAMI‐A and the myths in the field of ruthenium anticancer compounds: a personal perspective

E Alessio - European Journal of Inorganic Chemistry, 2017 - Wiley Online Library
As anticipated in the title, this contribution is basically divided into two, strictly connected,
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …

Recent developments on other platinum metal complexes as target-specific anticancer therapeutics

TS Prathima, B Choudhury, MG Ahmad… - Coordination Chemistry …, 2023 - Elsevier
Numerous biologically active metal complexes are reported for their unique features and
enhanced functions, particularly towards the inhibition of cancer progression. With the …